CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis
USA - NASDAQ:CPRX - US14888U1016 - Common Stock
22.88 USD
-0.3 (-1.29%)
We assign a fundamental rating of 8 out of 10 to CPRX. CPRX was compared to 533 industry peers in the Biotechnology industry. CPRX gets an excellent profitability rating and is at the same time showing great financial health properties. CPRX is evaluated to be cheap and growing strongly. This does not happen too often! These ratings could make CPRX a good candidate for value and growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
In the past year CPRX had a positive cash flow from operations.
Each year in the past 5 years CPRX has been profitable.
Each year in the past 5 years CPRX had a positive operating cash flow.
1.2 Ratios
The Return On Assets of CPRX (21.50%) is better than 97.19% of its industry peers.
The Return On Equity of CPRX (24.42%) is better than 96.62% of its industry peers.
CPRX has a Return On Invested Capital of 21.46%. This is amongst the best in the industry. CPRX outperforms 97.75% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 15.78%.
The last Return On Invested Capital (21.46%) for CPRX is above the 3 year average (20.43%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.5% | ||
| ROE | 24.42% | ||
| ROIC | 21.46% |
ROA(3y)18.83%
ROA(5y)22.42%
ROE(3y)22.83%
ROE(5y)26.36%
ROIC(3y)20.43%
ROIC(5y)19.73%
1.3 Margins
The Profit Margin of CPRX (37.42%) is better than 96.62% of its industry peers.
CPRX's Profit Margin has been stable in the last couple of years.
With an excellent Operating Margin value of 43.51%, CPRX belongs to the best of the industry, outperforming 99.25% of the companies in the same industry.
In the last couple of years the Operating Margin of CPRX has grown nicely.
CPRX has a Gross Margin of 85.78%. This is amongst the best in the industry. CPRX outperforms 87.99% of its industry peers.
CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 43.51% | ||
| PM (TTM) | 37.42% | ||
| GM | 85.78% |
OM growth 3Y2.14%
OM growth 5Y4.99%
PM growth 3Y5.94%
PM growth 5Y1.35%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
Compared to 1 year ago, CPRX has more shares outstanding
CPRX has more shares outstanding than it did 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 17.44 indicates that CPRX is not in any danger for bankruptcy at the moment.
CPRX has a Altman-Z score of 17.44. This is amongst the best in the industry. CPRX outperforms 89.12% of its industry peers.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 17.44 |
ROIC/WACC2.44
WACC8.78%
2.3 Liquidity
A Current Ratio of 6.72 indicates that CPRX has no problem at all paying its short term obligations.
The Current ratio of CPRX (6.72) is better than 68.86% of its industry peers.
A Quick Ratio of 6.55 indicates that CPRX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.55, CPRX is doing good in the industry, outperforming 68.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.72 | ||
| Quick Ratio | 6.55 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.76% over the past year.
Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 34.29% on average per year.
Looking at the last year, CPRX shows a very strong growth in Revenue. The Revenue has grown by 23.49%.
Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 36.89% on average per year.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)23.49%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
The Earnings Per Share is expected to grow by 26.50% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 11.10% on average over the next years. This is quite good.
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.5%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.1%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 13.30, the valuation of CPRX can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.44% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CPRX to the average of the S&P500 Index (25.89), we can say CPRX is valued slightly cheaper.
CPRX is valuated correctly with a Price/Forward Earnings ratio of 13.29.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.44% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.59, CPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.3 | ||
| Fwd PE | 13.29 |
4.2 Price Multiples
97.75% of the companies in the same industry are more expensive than CPRX, based on the Enterprise Value to EBITDA ratio.
98.50% of the companies in the same industry are more expensive than CPRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.2 | ||
| EV/EBITDA | 7.78 |
4.3 Compensation for Growth
CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)0.98
PEG (5Y)0.39
EPS Next 2Y14.64%
EPS Next 3Y10.93%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CPRX (11/17/2025, 1:46:57 PM)
22.88
-0.3 (-1.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.12%
Inst Owner Change1.29%
Ins Owners5.59%
Ins Owner Change1.92%
Market Cap2.80B
Revenue(TTM)491.73M
Net Income(TTM)209.00M
Analysts88.57
Price Target34.68 (51.57%)
Short Float %7.36%
Short Ratio5.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.95%
Min EPS beat(2)4.13%
Max EPS beat(2)29.76%
EPS beat(4)4
Avg EPS beat(4)18.54%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)15.48%
EPS beat(12)11
Avg EPS beat(12)12.83%
EPS beat(16)12
Avg EPS beat(16)7.88%
Revenue beat(2)2
Avg Revenue beat(2)3.81%
Min Revenue beat(2)2.19%
Max Revenue beat(2)5.44%
Revenue beat(4)4
Avg Revenue beat(4)3.37%
Min Revenue beat(4)2.19%
Max Revenue beat(4)5.44%
Revenue beat(8)7
Avg Revenue beat(8)2.76%
Revenue beat(12)11
Avg Revenue beat(12)3.19%
Revenue beat(16)13
Avg Revenue beat(16)2.7%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.6%
EPS NY rev (1m)0.14%
EPS NY rev (3m)-0.14%
Revenue NQ rev (1m)-0.31%
Revenue NQ rev (3m)-1.53%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.3 | ||
| Fwd PE | 13.29 | ||
| P/S | 5.01 | ||
| P/FCF | 10.2 | ||
| P/OCF | 10.18 | ||
| P/B | 3.27 | ||
| P/tB | 3.9 | ||
| EV/EBITDA | 7.78 |
EPS(TTM)1.72
EY7.52%
EPS(NY)1.72
Fwd EY7.53%
FCF(TTM)2.24
FCFY9.81%
OCF(TTM)2.25
OCFY9.82%
SpS4.56
BVpS6.99
TBVpS5.87
PEG (NY)0.98
PEG (5Y)0.39
Graham Number16.45
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.5% | ||
| ROE | 24.42% | ||
| ROCE | 28.29% | ||
| ROIC | 21.46% | ||
| ROICexc | 89.4% | ||
| ROICexgc | 270.29% | ||
| OM | 43.51% | ||
| PM (TTM) | 37.42% | ||
| GM | 85.78% | ||
| FCFM | 49.17% |
ROA(3y)18.83%
ROA(5y)22.42%
ROE(3y)22.83%
ROE(5y)26.36%
ROIC(3y)20.43%
ROIC(5y)19.73%
ROICexc(3y)163.12%
ROICexc(5y)159.95%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.94%
ROCE(5y)26.01%
ROICexgc growth 3Y9.38%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.1%
ROICexc growth 5YN/A
OM growth 3Y2.14%
OM growth 5Y4.99%
PM growth 3Y5.94%
PM growth 5Y1.35%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1% | ||
| Cap/Sales | 0.07% | ||
| Interest Coverage | 164.19 | ||
| Cash Conversion | 97.92% | ||
| Profit Quality | 131.4% | ||
| Current Ratio | 6.72 | ||
| Quick Ratio | 6.55 | ||
| Altman-Z | 17.44 |
F-Score6
WACC8.78%
ROIC/WACC2.44
Cap/Depr(3y)0.73%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.7%
Profit Quality(5y)139.69%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.5%
Revenue 1Y (TTM)23.49%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.1%
EBIT growth 1Y183.82%
EBIT growth 3Y54.97%
EBIT growth 5Y43.72%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y121.47%
FCF growth 3Y59.15%
FCF growth 5Y47.24%
OCF growth 1Y121.6%
OCF growth 3Y58.39%
OCF growth 5Y47.31%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the financial health of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The financial health rating of CATALYST PHARMACEUTICALS INC (CPRX) is 8 / 10.